FIELD: pharmaceutical industry.
SUBSTANCE: albumin-binding prodrugs derived from auristatin E, which can be used for the treatment of malignant diseases.
EFFECT: reduction in cytotoxicity compared to an equivalent dose of the unmodified active agent.
18 cl, 25 dwg, 5 ex
Title | Year | Author | Number |
---|---|---|---|
DRUG DELIVERY SYSTEMS BASED ON MAYTANSINOID | 2018 |
|
RU2783076C2 |
DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | 2016 |
|
RU2748992C2 |
IMAGING MEANS FOR RADIOLABELED EXOGENOUS AND ENDOGENOUS ALBUMIN | 2019 |
|
RU2819907C2 |
RADIOACTIVE LABELLED PEPTIDES BINDING TO HER2 | 2011 |
|
RU2592685C2 |
MONOMETHYL AURISTATIN E CONJUGATE FOR PREPARING A COMPOSITION FOR TREATING PROSTATE CANCER | 2019 |
|
RU2729192C1 |
VACCINE COMPOSITIONS | 2010 |
|
RU2581020C2 |
ANTICANCER PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATING BREAST CANCER | 2015 |
|
RU2581022C1 |
PHARMACEUTICAL COMPOSITIONS OF SAPOSIN C AND METHODS FOR TREATING CANCER | 2018 |
|
RU2767199C1 |
STABLE PHARMACEUTICAL PREPARATION BASED ON THE PD-1 ANTIBODY AND ITS USE IN MEDICINE | 2016 |
|
RU2731418C2 |
RADIOACTIVE LABELING SET AND BINDING ANALYSIS | 2000 |
|
RU2251110C2 |
Authors
Dates
2023-04-28—Published
2018-11-30—Filed